



2024 Connecting Women Lunch Sponsors

PREMIER SPONSOR



CSL is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies.

Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit [CSL.com/Vita](https://www.csl.com/Vita) and follow us on [Twitter.com/CSL](https://twitter.com/CSL).

MAJOR SPONSORS



CITY OF MELBOURNE

Melbourne City Council is the local government body responsible for the municipality of Melbourne. The Council consists of a lord mayor, a deputy lord mayor and nine councillors.

Elected by the community, the Council is the decision-making body that sets the strategic direction and policy of the municipality. It delivers the four-year Council Plan, which sets out what the Council will achieve during its four-year term to further the community vision; and the Annual Plan and Budget, which describes the Council's key objectives and activities for each 12-month period.





Phillips Ormonde Fitzpatrick are the IP protection people who are great to work with, transforming creativity and innovation into commercial edge. We have been in operation for over 130 years and are a market leader in the IP profession, managing our client's IP in Australia and internationally from inception to commercialisation, enforcement, litigation, and defence.

Our professionals work with innovators at the cutting edge of advancements in science and technology with bringing products and services to market. We embrace diversity and proudly recognise women in leadership and are delighted to be an inaugural sponsor of the BioMelbourne Network Women's luncheon.

R&DIUM CAPITAL

Radium Capital is Australia's market leader in R&D financing. We were formed by entrepreneurs for entrepreneurs. That's why we don't think like a bank!

We believe businesses with R&D should have access to capital when they need it. So, we created Radium Advances to provide quick, easy and early access to up to 80% of your expected R&D tax incentive refund. Radium Advances are available as a one-off cash injection or can be used strategically multiple times throughout the year to smooth cash flow. The more you use Radium Advances the more your R&D benefits. Under a quarterly model, for the same expenditure, you can;

- boost your R&D spend by 50% or reduce your outlay by 33%.
- reinvest up to 150% of R&D expenditure back into R&D.

Since launching in 2017, Radium Capital has provided over \$700m of funding to Australian innovation businesses. Find out how innovators across Australia are using non-dilutive R&D financing to accelerate growth, attract other sources of funding and smooth cash flow at radiumcapital.com.au





SIGNATURE SPONSORS



Avatar Brokers has been one of Australia's leading insurance specialist brokerages for over 20 years. As industry pioneers and a fully independent brokerage, we stand at the forefront of specialisation, catering to innovative enterprises. Our expert knowledge empowers us to deliver progressive risk management solutions. Our clients consist of visionaries, disruptors, and game-changers searching for proactive partners who grasp the intricacies of their unique products and the ever-shifting business landscape. And that's precisely where Avatar's exceptional specialist knowledge and expertise come into play.

Being the only endorsed broker for key life science bodies, Avatar brings unparalleled expertise to help safeguard the life science industry's success. A substantial 70% of our client portfolio stems from technology, life sciences, green energy and related service providers, showcasing our expertise in serving dynamic and innovative businesses. We are proud to be recognised as the endorsed broker for AusBiotech, BioMelbourne Network, Life Sciences Queensland, and the Affiliated Partner of TechAssure. Our trusted reputation is a testament to our unwavering commitment to excellence and our deep understanding of the specific risks our clients face. And it's why we are recognised as the Accredited Industry Expert for Victorian Leaders.

We understand that managing risk can be complex and time-consuming. That's why we've made it easy. Our specialised team is well-versed in life science companies' unique challenges, enabling us to streamline the risk transfer process, ensuring our clients are protected without the hassle and can focus unwaveringly on what truly matters most to their business – their continued growth and success.



4DMedical is a global medical technology company that has created a breakthrough in the ability to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology®, 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and more sensitively as patients breathe. This technology powers 4DMedical's XV Lung Ventilation Analysis Software (XV LVAS®)—the first modality to dynamically quantify ventilation throughout the lungs—and its Computed Tomography-enabled counterpart software, CT LVAS™. Both products are listed on the TGA ARTG and cleared by the FDA.





Reports generated by XV LVAS and CT LVAS are prepared using 4DMedical's Software as a Service delivery model, utilizing existing clinical imaging equipment or the Company's groundbreaking XV Scanner.

In 2023, 4DMedical acquired Imbio, a leader in artificial intelligence medical imaging solutions for chronic lung and cardiothoracic diseases. Imbio's regulatory-cleared solutions are revolutionizing the way patients are discovered, diagnosed, and treated, enhancing physician productivity and providing more personalized care for patients.

SUPPORTING SPONSORS



Brandon Capital is Australasia's leading life science venture capital firm, with a strong global presence supported by key partnerships and team members across the US and UK. From early-stage seed investment through to expansion capital, Brandon Capital supports life science companies from proof-of-concept through to commercialisation.

Managed by Brandon Capital, Brandon BioCatalyst is a unique collaboration of over 50 leading medical research institutes, investors, and government united by a single purpose: progressing the next generation of medical therapies and technology which improve health and save lives.

<https://brandoncapital.vc/> | <https://brandonbiocatalyst.com/>



Cell Therapies has been the leading cell and gene therapy manufacturing organisation in Australia for over 20 years. Cell Therapies is at the forefront of bringing approved therapies to Australian patients and working with Australian researchers and biotech companies to develop home-grown cell and gene therapy products. Our expertise spans across the product development pipeline from first-in-human, early to late phase clinical trials, through to commercial supply for patients across Australia and the Asia Pacific region.

Cell Therapies is Australia's only TGA-licensed biomedical manufacturing facility where CAR T-cells and other "living" cell-based therapies can be produced at commercial volumes. The facility supports manufacture of both





autologous and allogeneic products and includes large-scale high-throughput GMP manufacturing suites for late-phase and commercial supply with a production capacity of up to 2,000 patient doses per year. Located in the Peter MacCallum Cancer Centre in the Parkville Biomedical Precinct, Melbourne, Cell Therapies meets many international regulatory agency requirements, including those of the Australian TGA, the US FDA, Japan's PMDA, and Europe's EMA.



Crux Biolabs is an Australian bioanalytical laboratory specialising in PBMC processing, pharmacodynamics (biomarker, flow cytometry, ELISpot, and ADA) and pharmacokinetics (large and small molecule) for clinical research.

Our expert scientists can customise and validate a wide range of biomarker and cell assays in our ISO 17025-accredited lab in Melbourne, Australia. We also offer PBMC processing in Sydney with our dedicated satellite laboratory. From Q3 2024, we will extend our PBMC processing service to Wellington for New Zealand-based studies.

We understand that each study is unique. That's why we take pride in becoming an extension of your team to deliver the best outcome for your clinical studies. Crux Biolabs - where science leads.



Telix is a commercial-stage biopharmaceutical company focused on the development and commercialisation of therapeutic and diagnostic radiopharmaceuticals. We are headquartered in Melbourne, with operations in the U.S., Europe, and Japan. Our mission is to be the global leader in our field by combining therapeutic and diagnostic modalities for the benefit of patients, an innovative precision medicine concept generally referred to as 'theranostics'.

We have an extensive pipeline of theranostic radiopharmaceutical candidates, with a focus on urologic oncology (prostate and kidney), neuro-oncology (glioma), musculoskeletal oncology (sarcoma) and bone marrow conditioning. Our theranostic approach is intended to use imaging and therapy together to 'see and treat' cancer and rare diseases, to both better inform treatment decisions and deliver personalised therapy for patients.





Our lead imaging product – Illuccix® for prostate cancer imaging (also known as ⁶⁸Ga-PSMA-11) is commercially available in the U.S., Australia, Canada and New Zealand.

Visit <https://telixpharma.com/> for more or follow us on [LinkedIn](#).



For more than 50 years, La Trobe University has been transforming people and societies. The University works collaboratively across disciplines and with partners to develop fresh ways of thinking and conducting research – constantly seeking new ways to engage with and better serve its partners and communities, to build relationships and develop solutions for the issues facing society.

Ranked in the top one per cent of universities worldwide,¹ La Trobe is firmly positioned in the top 400 of all three major world university rankings. In 2021, the respected Times Higher Education World Ranking placed La Trobe at 218 globally,² marking the second year running the University has been named in the world's top 250.

1. Times Higher Education (THE), 2021, World University Rankings 2022; Consejo Superior de Investigaciones Científicas (CSIC), 2020, Ranking Web of Universities.

2. Times Higher Education (THE), 2021, World University Rankings 2022.

Read more about La Trobe University here: <https://www.latrobe.edu.au/>



mexec 'connects people for success'

mexec is an Executive Search Recruitment firm that that assists companies in the biotechnology, health and innovation sectors to build their leadership teams.

We also provide support to individuals seeking to transition to new roles.

Reach out to us today on careers@mexec.com or visit our website at www.mexec.com





As the world's leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide – from veterinarians and pet owners to livestock farmers and ranchers. The company's leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of \$8.5 billion in 2023 with approximately 14,100 employees.

